MangoRx Acquires Patent Portfolio For Total Of $20M Through Issuance Of 980K Of 6% Series C Convertible Preferred Shares
MangoRx Acquires Patent Portfolio For Total Of $20M Through Issuance Of 980K Of 6% Series C Convertible Preferred Shares
Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the area of erectile dysfunction (ED), hair
Mangoceuticals, Inc.（纳斯达克股票代码：MGRX）（“MangorX” 或 “公司”），一家专注于开发、营销和销售勃起功能障碍（ED）、头发领域的各种男性健康和保健产品的公司
Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the area of erectile dysfunction (ED), hair growth and hormone replacement therapies is excited to announce that it has acquired a global patent portfolio for a pioneering oral solution and application aimed to combat and prevent a spectrum of infections, including the common cold, respiratory diseases, and orally transmitted diseases such as human papillomavirus (HPV) (the "Patent Portfolio") from Intramont Technologies, Inc. ("Intramont"), pursuant to a Patent Purchase Agreement ("PPA").
Mangoceuticals, Inc.（纳斯达克股票代码：MGRX）（“MangorX” 或 “公司”）是一家专注于开发、营销和销售勃起功能障碍（ED）、头发生长和激素替代疗法领域各种男士健康和保健产品的公司，很高兴地宣布，它已获得一项旨在对抗和预防一系列感染的开创性口服溶液和应用的全球专利组合，包括普通感冒、呼吸系统疾病和人乳头瘤病毒（HPV）等口腔传播疾病（“专利组合”）根据专利购买协议（“PPA”），来自英特蒙特科技公司（“Intramont”）。